Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | ACHE | P22303 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.37 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.37 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29427076 | 1.00 | ALDH1A1 (0.48) | ALDH1A1ACHECYP3A4PTPN1MAPK1 | |
| Ammonia Solution, Strong SCHEMBL1085422 | 0.98 | ALDH1A1 (0.46) | ALDH1A1ACHECYP3A4PTPN1MAPK1 | |
| SCHEMBL6726921 | 0.84 | TACR1 (0.36) | ALDH1A1ACHEPTPN1MAPK1MAOB | |
| SCHEMBL202288 | 0.84 | ALDH1A1 (0.69) | ALDH1A1CYP3A4MAPK1CYP1A1CYP1B1 | |
| SCHEMBL309832 | 0.84 | ALDH1A1 (0.59) | ALDH1A1CYP3A4MAPK1CYP1A1CYP1B1 | |
| SCHEMBL2999328 | 0.81 | ALDH1A1 (0.65) | ALDH1A1CYP3A4MAPK1CYP1A1CYP1B1 | |
| SCHEMBL3966378 | 0.81 | ALDH1A1 (0.65) | ALDH1A1CYP3A4CYP1A1CYP1B1MAOB | |
| SCHEMBL145855 | 0.81 | ALDH1A1 (0.62) | ALDH1A1ACHECYP3A4PTPN1MAPK1 | |
| SCHEMBL12501 | 0.81 | ALDH1A1 (0.73) | ALDH1A1ACHECYP3A4PTPN1MAPK1 | |
| SCHEMBL29587173 | 0.78 | ALDH1A1 (0.59) | ALDH1A1ACHECYP3A4PTPN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 276 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107501132-A | A kind of preparation technology of the Methoxybenzenesulfonyl chloride of 3 methyl 5 | 贵州大学 | 2017-12-22 | — | — | CN | claimed |
| WO-2007117482-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | claimed |
| US-20260062393-A1 | Compounds | CTXT PTY LTD (AU) | 2026-03-05 | — | — | US | disclosed |
| EP-4651955-A1 | INHIBITOR COMPOUNDS | Neophore Limited (GB) | 2025-11-26 | — | — | EP | disclosed |
| US-12365655-B2 | Compounds | CTXT PTY LTD (AU) | 2025-07-22 | — | — | US | disclosed |
| CN-112334466-B | Compounds of formula (I) | CTXT私人有限公司 | 2025-05-30 | — | — | CN | disclosed |
| US-12150934-B2 | Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseases | BANTAM PHARMACEUTICAL, LLC (US) | 2024-11-26 | — | — | US | disclosed |
| EP-3802492-B1 | COMPOUNDS USEFUL IN THE TREATMENT OF DISORDERS ASSOCIATED WITH MUTANT RAS | THE INSTITUTE OF CANCER RES ROYAL CANCER HOSPITAL (GB) | 2024-11-06 | — | — | EP | disclosed |
| EP-4217062-B1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-09 | — | — | EP | disclosed |
| WO-2024153947-A1 | INHIBITOR COMPOUNDS | Neophore Limited (GB) | 2024-07-25 | — | — | WO | disclosed |
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-27 | — | — | US | disclosed |
| EP-0748311-B1 | THERAPEUTIC BENZONITRILES | WELLCOME FOUND (GB) | 1999-08-04 | — | — | EP | disclosed |
| US-5723452-A | Therapeutic benzonitriles | GLAXO WELLCOME INC. (US) | 1998-03-03 | — | — | US | disclosed |
| EP-0748311-A1 | THERAPEUTIC BENZONITRILES | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-12-18 | — | — | EP | disclosed |
| WO-1995023133-A1 | THERAPEUTIC BENZONITRILES | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-08-31 | — | — | WO | disclosed |
| EP-0229510-B1 | SULFINYL AND SULFONYL SUBSTITUTED-3-BENZAZEPINES | SMITHKLINE BEECHAM CORPORATION (US) | 1990-06-06 | — | — | EP | disclosed |
| US-4824839-A | Sulfinyl and sulfonyl substituted 2,3,4,5 tetrahydro-1H-3-benzazepines and their use in treating gastrointestinal motility disorders | SMITHKLINE BECKMAN CORPORATION (US) | 1989-04-25 | — | — | US | disclosed |
| EP-0229510-A1 | Sulfinyl and sulfonyl substituted-3-benzazepines | SMITHKLINE BEECHAM CORPORATION (US) | 1987-07-22 | — | — | EP | disclosed |
| CN-86108627-A | The 3-benzazepines that sulfinyl and sulphonyl replace | — | 1987-07-22 | — | — | CN | disclosed |
| US-4659706-A | Sulfinyl and sulfonyl substituted 3-benzazepines | SMITHKLINE BECKMAN CORPORATION (US) | 1987-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062393-A1 | Compounds | SCN2B, ABCB11, SCN1B | ALDH1A1 1864/4885ACHE 2636/4885CYP3A4 329/4885 |
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | ALDH1A1 472/4885ACHE 52/4885CYP3A4 1069/4885 |
| US-12365655-B2 | Compounds | SLC10A1, ABCB11, PCSK9 | ALDH1A1 982/4885ACHE 1768/4885CYP3A4 50/4885 |
| US-12150934-B2 | Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseases | KRAS, TP53, CCNA1 | ALDH1A1 480/4885ACHE 3540/4885CYP3A4 1561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.